erdafitinib
SpainDrugs containing this active substance
-
It is used in adults to treat urothelial carcinoma (bladder and urinary tract cancer) that is locally advanced and unresectable, or metastatic, provided the cancer has specific alterations in the FGFR3 gene and has worsened after immunotherapy treatment.
Form: tablets, film-coated
Active substance Dosage erdafitinib 3 mg Manufacturer: Janssen-Cilag International N.V
-
It is used in adults to treat locally advanced and unresectable or metastatic urothelial carcinoma (cancer of the bladder and urinary tract), provided that the cancer cells have FGFR3 gene alterations and the cancer has progressed following immunotherapy.
Form: tablets, film-coated
Active substance Dosage erdafitinib 5 mg Manufacturer: Janssen-Cilag International N.V
-
It is used in adults to treat locally advanced unresectable or metastatic urothelial carcinoma (cancer of the bladder and urinary tract), provided that the cancer presents certain alterations in the FGFR3 gene and has worsened following immunotherapy treatment.
Form: tablets, film-coated
Active substance Dosage erdafitinib 4 mg Manufacturer: Janssen-Cilag International N.V